MA29600B1 - Utilisation de sanglifehrine dans le virus de l'hepatite c - Google Patents
Utilisation de sanglifehrine dans le virus de l'hepatite cInfo
- Publication number
- MA29600B1 MA29600B1 MA30507A MA30507A MA29600B1 MA 29600 B1 MA29600 B1 MA 29600B1 MA 30507 A MA30507 A MA 30507A MA 30507 A MA30507 A MA 30507A MA 29600 B1 MA29600 B1 MA 29600B1
- Authority
- MA
- Morocco
- Prior art keywords
- hepatitis
- sanglifehrin
- virus
- hepatic
- bloodlifetin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La présente invention décrit l'utilisation d'un composé macrolide tel qu'une sangliféhrine pour le traitement et la prévention de l'hépatite C et de maladies s'y rapportant telles que la fibrose hépatique, la cirrhose hépatique et le carcinome hépatocellulaire.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US69149705P | 2005-06-17 | 2005-06-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA29600B1 true MA29600B1 (fr) | 2008-07-01 |
Family
ID=37075234
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA30507A MA29600B1 (fr) | 2005-06-17 | 2007-12-26 | Utilisation de sanglifehrine dans le virus de l'hepatite c |
Country Status (21)
Country | Link |
---|---|
US (1) | US20090221598A1 (fr) |
EP (1) | EP1893211B1 (fr) |
JP (1) | JP2008546708A (fr) |
KR (1) | KR20080033274A (fr) |
CN (1) | CN101242842A (fr) |
AR (1) | AR054778A1 (fr) |
AT (1) | ATE524183T1 (fr) |
AU (1) | AU2006259348B2 (fr) |
BR (1) | BRPI0613142A2 (fr) |
CA (1) | CA2611151A1 (fr) |
EC (1) | ECSP078029A (fr) |
GT (1) | GT200600262A (fr) |
MA (1) | MA29600B1 (fr) |
MX (1) | MX2007016068A (fr) |
NO (1) | NO20080351L (fr) |
PE (1) | PE20070118A1 (fr) |
RU (1) | RU2427372C2 (fr) |
TN (1) | TNSN07477A1 (fr) |
TW (1) | TW200740438A (fr) |
WO (1) | WO2006138507A1 (fr) |
ZA (1) | ZA200710551B (fr) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5789190B2 (ja) | 2008-09-24 | 2015-10-07 | シャンハイ インスティテュート オブ オーガニック ケミストリー,チャイニーズ アカデミー オブ サイエンシズ | 新規の遺伝子クラスター |
WO2011011632A1 (fr) * | 2009-07-22 | 2011-01-27 | Tufts University | Procédés et compositions destinés à moduler le potentiel membranaire afin d'influencer le comportement de la cellule |
WO2011063076A1 (fr) | 2009-11-19 | 2011-05-26 | Itherx Pharmaceuticals, Inc. | Méthodes de traitement du virus de l'hépatite c avec des composés d'oxo-acétamide |
WO2011098805A1 (fr) | 2010-02-09 | 2011-08-18 | Biotica Technology Limited | Composés à base de sangliféhrine |
WO2011098808A1 (fr) | 2010-02-09 | 2011-08-18 | Biotica Technology Limited | Composés à base de sangliféhrine |
WO2011098809A1 (fr) | 2010-02-09 | 2011-08-18 | Biotica Technology Limited | Complexes à base de sangliféhrine |
GB201008123D0 (en) | 2010-05-17 | 2010-06-30 | Biotica Tech Ltd | Novel compounds |
AR084217A1 (es) | 2010-12-10 | 2013-05-02 | Gilead Sciences Inc | Inhibidores macrociclicos de virus flaviviridae |
JP6086869B2 (ja) * | 2010-12-20 | 2017-03-08 | ネウロビベ プハルマセウトイカル エービー | サングリフェリン誘導体及びそれらの製造方法 |
JO3063B1 (ar) | 2011-03-29 | 2017-03-15 | Neurovive Pharmaceutical Ab | مركب مبتكر وطرق لانتاجه |
WO2012145426A1 (fr) | 2011-04-18 | 2012-10-26 | The Trustees Of Columbia University In The City Of New York | Procédés pour traiter un cancer utilisant la cyclosporine et des dérivés de cyclosporine |
GB201118334D0 (en) | 2011-10-24 | 2011-12-07 | Biotica Tech Ltd | Novel dosage form |
AR091279A1 (es) | 2012-06-08 | 2015-01-21 | Gilead Sciences Inc | Inhibidores macrociclicos de virus flaviviridae |
IN2014MN02658A (fr) * | 2012-06-08 | 2015-08-21 | Gilead Sciences Inc | |
SI2861604T1 (sl) | 2012-06-08 | 2017-05-31 | Gilead Sciences, Inc. | Makrociklični inhibitorji flavivirusov |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4917888A (en) | 1985-06-26 | 1990-04-17 | Cetus Corporation | Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation |
US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
JP2514950B2 (ja) | 1986-03-10 | 1996-07-10 | エフ・ホフマン―ラ ロシユ アーゲー | 化学修飾蛋白質,その製造法および中間体 |
KR0148748B1 (ko) | 1988-09-16 | 1998-08-17 | 장 크라메르, 한스 루돌프 하우스 | 사이클로스포린을 함유하는 약학조성물 |
CA2079912C (fr) | 1990-04-06 | 2000-07-11 | Gregory Reyes | Epitopes du virus de l'hepatite c |
US5595732A (en) | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
US5382657A (en) | 1992-08-26 | 1995-01-17 | Hoffmann-La Roche Inc. | Peg-interferon conjugates |
GB9318612D0 (en) | 1993-09-08 | 1993-10-27 | Sandoz Ltd | An assay |
AU691225B2 (en) | 1993-11-10 | 1998-05-14 | Schering Corporation | Improved interferon polymer conjugates |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
AR006514A1 (es) | 1995-07-04 | 1999-09-08 | Sandoz Ag | Un macrolido, sus usos, un proceso para producirlo, un aislado biologicamente puro capaz de producirlo, y una composicion farmaceutica quelo comprende |
US6124453A (en) | 1995-07-04 | 2000-09-26 | Novartis Ag | Macrolides |
US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
US5990276A (en) | 1996-05-10 | 1999-11-23 | Schering Corporation | Synthetic inhibitors of hepatitis C virus NS3 protease |
TR199901602T2 (xx) | 1996-10-18 | 1999-10-21 | Vertex Pharmaceuticals Incorporated | Serin proteazlar�n ve �zel olarak hepatit C vir�s� NS3 proteaz�n�n inhibit�rleri. |
GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
US6004933A (en) | 1997-04-25 | 1999-12-21 | Cortech Inc. | Cysteine protease inhibitors |
US6143715A (en) | 1997-08-11 | 2000-11-07 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C inhibitor peptide analogues |
GB9806815D0 (en) | 1998-03-30 | 1998-05-27 | Hoffmann La Roche | Amino acid derivatives |
GB9811854D0 (en) | 1998-06-02 | 1998-07-29 | Ciba Geigy Ag | Organic compounds |
US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
US6444652B1 (en) | 1998-08-10 | 2002-09-03 | Novirio Pharmaceuticals Limited | β-L-2'-deoxy-nucleosides for the treatment of hepatitis B |
MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
ATE275406T1 (de) | 2000-05-26 | 2004-09-15 | Idenix Cayman Ltd | Methoden zur behandlung von delta hepatitis virus infektionen mit beta-l-2' deoxy-nucleosiden |
CN101099745A (zh) | 2000-05-26 | 2008-01-09 | 艾登尼科斯(开曼)有限公司 | 处理黄病毒和瘟病毒的方法和组合物 |
MY141594A (en) | 2000-06-15 | 2010-05-14 | Novirio Pharmaceuticals Ltd | 3'-PRODRUGS OF 2'-DEOXY-ß-L-NUCLEOSIDES |
AU8063701A (en) | 2000-07-21 | 2002-02-05 | Schering Corp | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus |
AR029851A1 (es) | 2000-07-21 | 2003-07-16 | Dendreon Corp | Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c |
US20020068702A1 (en) | 2000-07-21 | 2002-06-06 | Marguerita Lim-Wilby | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus |
AU2001255070A1 (en) | 2000-08-28 | 2002-03-13 | Jin-Sub Kim | Generator of two-wheeled vehicle and lighting system thereby |
JP3889708B2 (ja) | 2000-11-20 | 2007-03-07 | ブリストル−マイヤーズ スクイブ カンパニー | C型肝炎トリペプチド阻害剤 |
US6911428B2 (en) | 2000-12-12 | 2005-06-28 | Schering Corporation | Diaryl peptides as NS3-serine protease inhibitors of hepatitis C virus |
US6727366B2 (en) | 2000-12-13 | 2004-04-27 | Bristol-Myers Squibb Pharma Company | Imidazolidinones and their related derivatives as hepatitis C virus NS3 protease inhibitors |
AU2002230763A1 (en) | 2000-12-13 | 2008-01-03 | Bristol-Myers Squibb Pharma Company | Inhibitors of hepatitis c virus ns3 protease |
US7456155B2 (en) | 2002-06-28 | 2008-11-25 | Idenix Pharmaceuticals, Inc. | 2′-C-methyl-3′-O-L-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections |
GB0320638D0 (en) | 2003-09-03 | 2003-10-01 | Novartis Ag | Organic compounds |
RS51614B (en) * | 2004-10-01 | 2011-08-31 | Debiopharm S.A. | USE OF [D-MEAL] 3- [ETVAL] 4-CYCLOSPORINE FOR THE TREATMENT OF HEPATITIS C INFECTIONS |
KR20070087624A (ko) * | 2004-12-23 | 2007-08-28 | 노파르티스 아게 | Hcv 치료용 조성물 |
-
2006
- 2006-06-15 JP JP2008517117A patent/JP2008546708A/ja active Pending
- 2006-06-15 KR KR1020087001271A patent/KR20080033274A/ko not_active Application Discontinuation
- 2006-06-15 BR BRPI0613142-5A patent/BRPI0613142A2/pt not_active IP Right Cessation
- 2006-06-15 WO PCT/US2006/023394 patent/WO2006138507A1/fr active Application Filing
- 2006-06-15 CN CNA2006800297685A patent/CN101242842A/zh active Pending
- 2006-06-15 US US11/917,781 patent/US20090221598A1/en not_active Abandoned
- 2006-06-15 AT AT06784962T patent/ATE524183T1/de not_active IP Right Cessation
- 2006-06-15 CA CA002611151A patent/CA2611151A1/fr not_active Abandoned
- 2006-06-15 RU RU2008100587/15A patent/RU2427372C2/ru not_active IP Right Cessation
- 2006-06-15 MX MX2007016068A patent/MX2007016068A/es not_active Application Discontinuation
- 2006-06-15 EP EP06784962A patent/EP1893211B1/fr not_active Not-in-force
- 2006-06-15 AU AU2006259348A patent/AU2006259348B2/en not_active Ceased
- 2006-06-15 AR ARP060102543A patent/AR054778A1/es unknown
- 2006-06-16 GT GT200600262A patent/GT200600262A/es unknown
- 2006-06-16 TW TW095121787A patent/TW200740438A/zh unknown
- 2006-06-16 PE PE2006000682A patent/PE20070118A1/es not_active Application Discontinuation
-
2007
- 2007-12-04 ZA ZA200710551A patent/ZA200710551B/xx unknown
- 2007-12-14 TN TNP2007000477A patent/TNSN07477A1/en unknown
- 2007-12-17 EC EC2007008029A patent/ECSP078029A/es unknown
- 2007-12-26 MA MA30507A patent/MA29600B1/fr unknown
-
2008
- 2008-01-16 NO NO20080351A patent/NO20080351L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
BRPI0613142A2 (pt) | 2010-12-21 |
NO20080351L (no) | 2008-03-14 |
JP2008546708A (ja) | 2008-12-25 |
MX2007016068A (es) | 2008-03-10 |
PE20070118A1 (es) | 2007-02-23 |
ZA200710551B (en) | 2008-11-26 |
WO2006138507A1 (fr) | 2006-12-28 |
KR20080033274A (ko) | 2008-04-16 |
ECSP078029A (es) | 2008-01-23 |
EP1893211A1 (fr) | 2008-03-05 |
CN101242842A (zh) | 2008-08-13 |
TNSN07477A1 (en) | 2009-03-17 |
AU2006259348B2 (en) | 2010-07-22 |
RU2008100587A (ru) | 2009-07-27 |
EP1893211B1 (fr) | 2011-09-14 |
TW200740438A (en) | 2007-11-01 |
ATE524183T1 (de) | 2011-09-15 |
RU2427372C2 (ru) | 2011-08-27 |
AR054778A1 (es) | 2007-07-18 |
GT200600262A (es) | 2007-03-28 |
US20090221598A1 (en) | 2009-09-03 |
CA2611151A1 (fr) | 2006-12-28 |
AU2006259348A1 (en) | 2006-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA29600B1 (fr) | Utilisation de sanglifehrine dans le virus de l'hepatite c | |
MA32806B1 (fr) | Thérapie de combinaison avec des peptides époxycétones | |
WO2007112288A3 (fr) | Composition cardiovasculaire et utilisation de ladite composition pour le traitement de la maladie d'alzheimer | |
WO2006066079A3 (fr) | Composes de pyridazinone | |
WO2005074598A3 (fr) | Composes precurseurs de nitroxyle et methodes d'utilisation | |
DE602005015834D1 (de) | 3,4-(cyclopentyl)kondensierte prolinverbindungen als inhibitoren der ns3-serinprotease des hepatitis-c-virus | |
MXPA02012443A (es) | Profarmaco en 3'' de 2'-desoxi-beta-l-nucleosidos. | |
IS8448A (is) | Lifrarbólgu C-veirutálmar | |
NO20055516L (no) | Kannabinoidreceptorligander og anvendelser derav | |
TW200602037A (en) | Novel compounds as inhibitors of hepatitis C virus NS3 serine protease | |
NO20091576L (no) | Sammensetninger av TRL-ligander og antiviraler | |
MY145074A (en) | Thiazolidin-4-one derivatives | |
UA85559C2 (en) | Aminobenzophenone compounds | |
MA28583B1 (fr) | Dérivés de pyrimidine pour le traitement d'une croissance cellulaire anormale | |
WO2007150001A8 (fr) | Composés de la pyrro[1,2-b]pyridazinone | |
SG167670A1 (en) | Aminocyclohexyl ether compounds and uses thereof | |
NO20053348D0 (no) | Farmasoytisk sammensetning for behandling av virusangrep. | |
MA29097B1 (fr) | Composes pour le traitement des infections virales par flaviviridae | |
UA102414C2 (ru) | Циклоундекадепсипептидные соединения для лечения инфекций, вызванных вирусом гепатита с | |
CL2003002293A1 (es) | Compuestos derivados de indazol; su composicion farmaceutica; su uso en el tratamiento de hipertension ocular. | |
CL2007000789A1 (es) | Compuestos derivados de malonamida, inhibidores de la gamma-secretasa; proceso de preparacion; composicion farmaceutica; y su uso en el tratamiento de la enfermedad de alzheimer. | |
ATE399532T1 (de) | Medizinische seife | |
NO20033318L (no) | 2H-1-benzopyranderivater, fremgangsmåte ved fremstilling samt farmasöytiskesammensetninger derav | |
BRPI0415571A (pt) | composições de limpeza | |
DE502005009978D1 (de) | Neue pulverinhalativa auf basis modifizierter laktosemischungen als hilfsstoff |